LONDON, Nov. 9, 2017 /PRNewswire/ --
Download the full report: https://www.reportbuyer.com/product/4093437
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 220.127.116.11) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 3, 1, 1, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Lymphoma, Non-Small Cell Lung Cancer, Colon Cancer, Colorectal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Astrocytoma, Bacterial Infections, Brain Tumor, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.
Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 22.214.171.124)- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type- The report summarizes all the dormant and discontinued pipeline projects- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 220.127.116.11) targeted therapeutics
Reasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 18.104.22.168)- Identify the use of drugs for target identification and drug repurposing- Identify potential new clients or partners in the target demographic- Develop strategic initiatives by understanding the focus areas of leading companies- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 22.214.171.124) development landscape- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Download the full report: https://www.reportbuyer.com/product/4093437
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information:Sarah SmithResearch Advisor at Reportbuyer.comEmail: [email protected]Tel: +44 208 816 85 48Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/cyclin-dependent-kinase-4-cell-division-protein-kinase-4-or-psk-j3-or-cdk4-or-ec-271122---pipeline-review-h2-2017-300553568.html
Subscribe to our Free Newsletters!
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...View All